NYSE / ETF
Virtus Biotech Clinical Trials ETF
BBC
Market price
$44.56
Source / date
Yahoo Finance chart · 10/2/2026, 7:55:52 PM
Exchange-traded prices may be delayed or unavailable from the quote provider. Company P/E-based scores, DCF valuation and forensic analysis do not apply to this listing; the analysis below uses the framework appropriate to its investment type.
DeepScreen investment analysis
ETF basket analysis
Refreshed 10/3/2026, 4:23:44 AM
Basket and structure
What the ETF owns and how the reported portfolio is classified.
- Benchmark / index
- Health
- Fund family
- Virtus
- Provider listing name
- Virtus LifeSci Biotech Clinical Trials ETF
- Legal structure
- Exchange Traded Fund
- Inception
- 2014-12-16
- First recorded trade
- 2014-12-17
Market listing label; not a verified fund-family disclosure.
Provider's first available trade, not necessarily fund launch.
Price history
Returns and risk calculated from available adjusted-price history, not a benchmark comparison.
- 1Y return
- 61.01%
- 3Y annualized return
- 32.86%
- 5Y annualized return
- -0.02%
- 3Y rolling median
- 1.12%
- 5Y rolling median
- -2.42%
- 52-week high
- $56.18
- 52-week low
- $27.62
Holding quality and valuation
Weighted fundamentals are calculated only across holdings for which usable company fundamentals are available.
- Weighted ROE
- -99.38%
- Weighted debt / equity
- 0.31
12.3% of reported weight covered.
Risk and concentration
Portfolio concentration plus realized and provider-published risk statistics.
- Top-10 weight
- 12.3%
- Largest sector
- healthcare · 100%
- Top-3 sector weight
- 100%
- 3Y max drawdown
- -50.64%
- 5Y max drawdown
- -67.34%
- 3Y volatility
- 39.62%
- Beta
- 1.18
Cost and execution
Ownership cost, tracking quality and exchange-trading friction where the source publishes them.
- Expense ratio / TER
- 0.65%
- Bid / ask spread
- 43.56%
- Premium / discount to NAV
- -0.839%
- AUM
- $50.32M
- Average volume
- 21.56K
- Latest session volume
- 9.01K
Not an average.
Top reported holdings
| Holding | Symbol | Weight |
|---|---|---|
| First Tracks Biotherapeutics Inc | TRAX | 1.48% |
| Amylyx Pharmaceuticals Inc | AMLX | 1.44% |
| Xencor Inc | XNCR | 1.38% |
| AbCellera Biologics Inc Ordinary Shares | ABCL | 1.37% |
| Monopar Therapeutics Inc | MNPR | 1.17% |
| AtaiBeckley Inc | ATAI | 1.17% |
| uniQure NV | QURE | 1.1% |
| MBX Biosciences Inc | MBX | 1.08% |
| Replimune Group Inc | REPL | 1.07% |
| SELLAS Life Sciences Group Inc | SLS | 1.06% |
DeepScreen displays verified values returned by its current sources. Metrics without a verified value are omitted rather than shown as empty placeholder cards.
Investment FAQ
Questions about Virtus Biotech Clinical Trials ETF
Research answers for Virtus Biotech Clinical Trials ETF (BBC) using the analysis framework appropriate to a ETF.
ETF FAQ
- What is Virtus Biotech Clinical Trials ETF (BBC)?
- Virtus Biotech Clinical Trials ETF is listed by DeepScreen as an exchange-traded fund. An ETF represents a portfolio of underlying assets while its units trade on an exchange during market hours. Research the fund's benchmark or strategy, holdings, concentration, costs, tracking quality and trading liquidity rather than evaluating it as a single operating company.
- How should I analyze Virtus Biotech Clinical Trials ETF?
- Analyze Virtus Biotech Clinical Trials ETF as a basket. Check what index or strategy it follows, the weight of its largest holdings and sectors, portfolio valuation and quality where meaningful, historical drawdown and volatility, expense ratio, tracking difference, tracking error, bid-ask spread, AUM, volume and premium or discount to NAV.
- What tracking metrics matter for Virtus Biotech Clinical Trials ETF?
- For a benchmark-tracking ETF, compare both tracking difference and tracking error. Tracking difference shows how far the fund's return has lagged or exceeded its benchmark over a period, while tracking error measures how variable that gap has been. Fees, cash holdings, rebalancing and implementation costs can affect both.
- Is Virtus Biotech Clinical Trials ETF a good ETF to buy?
- DeepScreen does not provide a personalized buy recommendation. Assess whether Virtus Biotech Clinical Trials ETF's benchmark or strategy, concentration, costs, tracking, liquidity and risk fit the exposure you are researching, and verify the issuer's latest factsheet and prospectus before making an investment decision.